Junod, Muhlstein, Lévy & Puder advised Barcelona-based hospitality recruitment platform Hosco on a successful EUR 3,400,000 intermediate Series-A financing round for hospitality network. Created in 2011 the hospitality recruitment platform Hosco is aimed at companies and individuals working in the hospitality and tourism sector. Through its website you can search for jobs in the sector, take […]
Perfect Holding announced the completion of the reverse takeover transaction (RTO) with Kinarus, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of viral, respiratory, and ophthalmic disease.
Engimmune Therapeutics, a Swiss biotech company based in Basel developing novel T-cell receptor (TCR)-based therapeutics, has closed a CHF 15.5m seed financing round. The round was led by the investors Pureos Bio-ventures and Novo
GHR Rechtsanwälte advised Koa Switzerland & Ghana on the establishment of Senior Loan Facilities. In February 2022, Koa Switzerland as well as KOA Impact Ghana entered into senior loan facilities with IDH Farmfit Fund B.
F10, a global innovation ecosystem for FinTech and InsurTech, has closed a new funding round in the mid-single-digit million range. Five T Fintech led the financing round with participation from Synpulse, United Fintech, On-Point, in
Westhive, providers of flexible office space, successfully closes its Series A financing round raising CHF 6.3 million. The round is co-led by the Fairway Family Office and Redstone powered MA Ventures, the corporate venture capital fund
Swiss biotech company, Engimmune Therapeutics completes its seed financing round raising CHF 15.5 million, co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch. Engimmune Therapeutics is a platform company using cutting-edge technologies
Inyova, a European impact investing platform, managed approximately CHF 173 million in assets as of the end of February 2022. The capital raised through the crowdinvesting is expected to enable the development of new features such as
Fu-Gen, an independent power producer and investor in renewable energy, has secured a strategic investment of more than EUR 320 million that will enable the company to advance renewable energy development. The funding received will be
CDR-Life, a Swiss biotechnology company pioneering a new and differentiated class of highly tumor-specific immune-oncology therapeutics, has completed its Series A financing raising USD 76 million. The round was led by Jeito Capital and RA Capital
